Hypomethylating Agents

Comparative Effectiveness of Azacitidine and Decitabine in TP53-Mutant Acute Myeloid Leukemia: Insights from the COMMAND Registry

By MedXY 09/12/2026

This study analyzes outcomes of azacitidine versus decitabine, with or without venetoclax, in TP53-mutant AML, revealing comparable survival outcomes and highlighting the independent prognostic impact of multi-hit TP53 status.

Clinical Updates Hematology-Oncology news Specialties

Oral Decitabine and Cedazuridine Maintenance Post-HSCT: Promising Strategy in High-Risk AML and MDS

By MedXY 09/21/2025

A phase 2 trial demonstrates that oral hypomethylating agent ASTX727, with optional donor lymphocyte infusion, shows encouraging disease-free survival and manageable safety after stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome.

Clinical Updates Hematology-Oncology news Specialties

Promising Frontline Triplet Therapies for IDH-Mutated AML Patients Ineligible for Intensive Chemotherapy

By MedXY 09/09/2025

Triplet regimens combining hypomethylating agents, venetoclax, and IDH inhibitors demonstrate high remission rates and survival in intensive chemotherapy-ineligible IDH-mutant AML patients, warranting further comparative studies against approved doublet therapies.